Cited by 110Ultrasound and Hyperthermia ApplicationsNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

High Intensity Focused Ultrasound-Responsive and Ultrastable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial–Mesenchymal Transition

Ma, Xiaotu, Yao, Meinan, Shi, Jiyun, Li, Xiaoda, Gao, Yu, Luo, Qi, Hou, Rui, Liang, Xiaolong +1 more·2020·ACS Nano

Abstract

Hypoxia is a hostile hallmark of most solid tumors, which often leads to multidrug resistance (MDR) and causes the failure of chemotherapy. Hypoxia also promotes epithelial–mesenchymal transition (EMT), leading to acceleration of tumor metastasis. Many chemotherapeutic drugs can further exacerbate hypoxia and thus promote metastasis. Therefore, relieving hypoxia is necessary for chemotherapy to inhibit both MDR and EMT. Herein, highly stable cerasomal perfluorocarbon nanodroplets with an atomic layer of polyorganosiloxane surface and pH-sensitive tumor-targeting peptide (D-vPCs-O2) were fabricated to co-deliver oxygen and therapeutic drug, doxorubicin. High-intensity focused ultrasound (HIFU) was utilized to trigger the co-release of doxorubicin and oxygen and simultaneously enhance ultrasound imaging, therefore achieving imaging-guided drug delivery. Mild-temperature HIFU (M-HIFU) not only triggered oxygen release from nanodroplets but also slightly elevated tumor temperature to accelerate tumor blood flow. The oxygen release and temperature elevation jointly relieved tumor hypoxia and alleviated MDR, which greatly enhanced the drug therapeutic efficacy as compared to clinically used doxorubicin and Doxil. Overall side effects were also largely reduced owing to the ultrastable drug loading of cerasome. The improvement of insufficient chemotherapy and the relief of tumor hypoxia corporately down-regulated TGF-β1, leading to the alleviation of EMT, and therefore significantly inhibited tumor metastasis. When “D-vPCs-O2 + M-HIFU” was utilized as a neoadjuvant chemotherapy, nanodroplets down-regulated heat shock proteins, reducing tumor relapse after the high-temperature HIFU (H-HIFU)-mediated hyperthermia ablation. The chemo-hyperthermia therapy totally eradicated tumors without any relapse or metastasis, providing a promising way to treat the triple-negative breast cancer, which is highly malignant, easily metastatic, and lacks effective treatments.

Integrity signals

Registry

Crossref · 10.1021/acsnano.0c07287

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies on the remission of hypoxic tumors in combination with various chemotherapeutic agents have shown increased mean survival time and/or decreased tumor growth/metastasis.

    “Several studies on the remission of hypoxic tumors in combination with various chemotherapeutic agents have shown increased mean survival time and/or decreased tumor growth/metastasis. 391 , 392”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ma, X., Yao, M., Shi, J., Li, X., Gao, Y., Luo, Q., Hou, R., Liang, X., & Wang, F.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Peking University (CN)
  • Peking University Third Hospital (CN)
Corresponding author
  • Liang, Xiaolong
  • Wang, Fan
Venue
ACS Nano
Published
2020-11-11
Volume
14
Issue
11
Pages
15904-15918
ISSN
  • 1936-0851 (ISSN-L)
  • 1936-086X
OpenAlex
W3104458648
Cited by
110
References
25
Citations by year
2026: 12 · 2025: 19 · 2024: 15 · 2023: 28 · 2022: 22 · 2021: 14
FWCI
5.03
Type
journal article
Language
en
Open access
closed
Locations
  • ACS Nano (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Science and Technology of the People's Republic of China (2016YFA0201400, 2017YFA0205600)
  • Peking University Third Hospital (BYSY2015023, BYSYZD2019018, jyzc2018-02)
  • National Natural Science Foundation of China (81571810, 81630045, 81771846, 81822022, 81927802)
  • Beijing Talents Foundation (2018000021223ZK48)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
high-intensity focused ultrasound, cerasomes, perfluorocarbon nanodroplets, tumor hypoxia, multidrug resistance, epithelial-mesenchymal transition, doxorubicin, oxygen delivery, ultrasound-triggered drug release, imaging-guided drug delivery, TGF-β1, metastasis, triple-negative breast cancer, neoadjuvant chemotherapy, heat shock proteins
MeSH terms
Doxorubicin, Fluorocarbons, Humans, Neoplasms, Drug Delivery Systems, Drug Resistance, Multiple, Cell Line, Tumor, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review